FOLR2 and acute myeloid leukemia: In particular, CART cells, engineered with synthetic polypeptides consisting of an extracellular variable fragment directed to a tumor antigen and an intracellular signaling domain, potentiated by the addition of costimulatory molecules in new generation models, have shown great success in relapsed/refractory ALL and may find a role in AML too, possibly targeting AML-associated/specific antigens like CD33, CD123, Lewis Y antigen, and folate receptor beta [123].